Much debate surrounds the matter of personalised medicine. The problem of new treatments at high costs is usually mentioned in relation with inequalities and problems of access to care. But there is also an urgent need to discuss the impossibility for many healthcare systems in the world to provide myriad new diagnostic procedures and treatments to all populations. In this editorial, the current situation from a global perspective will be analysed and the position of some of the leading cancer organisations will be presented. We also discuss some possible actions to be developed to overcome this urgent and contradictory situation.
There has been much discussion in the cancer community around socalled 'personalised medicine'. Controversy exists over its definition and about the likely impact personalised medicines will have on patients of different settings, genetic backgrounds and resources. There are also different names proposed: personalised medicine, precision medicine, molecular medicine and targeted therapies are some of them, and the imprecise definition adds some confusion to the subject.
We need to take into account different views according to the position of each player in the cancer care continuum: from the patient-doctor relationship to the criteria of medical societies and, moreover, public health perspectives. Each one has diverse considerations and deserves a separate evaluation.
Likewise, it is also relevant to reflect on different levels of analysis: from a global scale to regional or national guidelines and recommendations; from scientific societies' perspectives to a clinical level. In this editorial, the topic from a global public health perspective will be considered.
We are not considering this subject as a controversy between science and economy, or an argument against the urgent need for more and better knowledge on the mechanisms and processes in the development of cancer. We consider that this is a discussion about the best possible and more rational use of existing resources for cancer care and control and an analysis for better strategies. We also present some reflections on how to strategise and implement the existing available knowledge (that today only applies to around 10 % of the world's population) to be applicable to a broader portion of the globe. The price of targeted therapies has been set very high, and as more targeted therapies enter the market and are used as long-term maintenance therapy, the overall cost of cancer care will increase significantly. Under the current circumstances, targeted therapies will become unaffordable for many countries, even for the most developed.
World Health Organization Position
The World Health Organization (WHO) estimates that nearly one-third of the world's population does not have access to full and effective treatment with the medicines they need -this rises to over 50 % in the most underprivileged parts of the world. Even in highly developed countries, access to some drugs and the best available therapy is not guaranteed for everyone. There is little or no international funding for cancer treatment compared to the billions of dollars that are used for other health-related purposes.
WHO has previously produced recommendations on the essential drugs required for cancer therapy, and over the last 5 years several new anticancer drugs have been aggressively marketed. Most of these are costly and produce only limited benefits. 9 WHO divided currently available anti-cancer drugs into three priority groups (curable, increased curability-adjuvant and prolong survival).
Curable cancers and those cancers where the cost-benefit ratio clearly favours drug treatment can be managed appropriately with regimens based on only 17 drugs. All of these are available, at relatively low cost, as generic preparations and the wide availability of these drugs should be the first priority, especially for LMIC. 
Union for International Cancer Control Position
Worldwide access to the best possible cancer treatment, care
and support is a top UICC priority. To deliver on its vision of a world where cancer is eliminated as a major life-threatening disease for future generations, UICC is committed to participating in building collaboration and cooperation to address barriers in access to cancer drugs worldwide.
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Barriers to Access
Drug costs: The high price of patent-protected cancer drugs makes them unaffordable for many countries. Patent enforcement by pharmaceutical companies in underprivileged countries can also inhibit access.
Insufficient public funding of health: Governments in some countries do not provide reimbursement for essential cancer drugs. This means that patients have to pay for drugs themselves.
Poor infrastructure: Many countries lack the facilities necessary to enable complex cancer drug regimens to be administered safely and effectively.
Irrational use of cancer drugs:
There is a dearth of adequately trained health professionals who are competent to prescribe and administer cancer drugs. In addition, many countries lack national evidence-based treatment guidelines for the rational selection of cancer drugs. 
Overcoming Barriers
• Some pharmaceutical companies have established drug donation programmes to address access problems in underprivileged countries. Although useful in the short term, these programmes are not a long-term solution to cancer drug access.
• WHO has developed a list of essential cancer medicines, which is updated and revised biennially. This list is used to guide procurement of cancer drugs in many underprivileged and developing countries.
Currently it is under full review. This review was requested by UICC 
Conclusion
It is critical to recognise cancer as a health priority that requires adequate public funding within the context of a national cancer control plan. It is also urgent to provide rigorous and timely evaluation and licensing of all cancer drugs and to adopt a range of mechanisms to secure affordable prices for cancer drugs.
Worldwide access to the best possible cancer treatment, care and support is a major global priority and we all must be committed to participating in building collaboration and cooperation to address barriers in access to cancer drugs worldwide.
It is our obligation to promote the rational use of cancer drugs by preparing national guidelines for the treatment of common cancers and ensuring that the cancer drugs that are included in national guidelines are listed in the national formulary of essential medicines.
As it was said by Dr John Seffrin, Chief Executive Officer (CEO) of the American Cancer Society (ACS) in 2008: "Every patient -regardless of where he or she is born -deserves an equal chance at a long life and good health." n
